Physician profile
Michael H Piper
NPI 1609859024
$9,011.30
in general payments reported to CMS, 2019-2025
31 companies · $645 in 2025
The $645 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,926 · 2020: $254 · 2021: $1,060 · 2022: $1,371 · 2023: $1,923 · 2024: $1,832 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,399.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,080.55 | 2019-2025 | |
| Janssen Biotech, INC. | $1,691.61 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,071.40 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $773.59 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $651.62 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $465.45 | 2019-2024 | Epclusa |
| Regeneron Healthcare Solutions, INC. | $382.04 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $310.33 | 2019-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $242.02 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $229.21 | 2019-2025 | Tremfya |
| Pfizer INC. | $157.25 | 2019-2024 | |
| Boston Scientific Corporation | $122.15 | 2019 | |
| Ardelyx, INC. | $99.45 | 2023-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $78.38 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $77.20 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $74.35 | 2023 | |
| Qol Medical, LLC | $70.68 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $69.55 | 2019-2022 | |
| Redhill Biopharma INC. | $56.37 | 2021-2022 | |
| Cook Medical LLC | $47.68 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $45.13 | 2024 | Iqirvo |
| Organon LLC | $42.08 | 2023 | Hadlima, Renflexis |
| Welch Allyn | $34.46 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.92 | 2025 | Givlaari |
| Ethicon US, LLC | $21.17 | 2022 | |
| Aimmune Therapeutics, INC. | $20.98 | 2024 | |
| Allergan, INC. | $15.48 | 2019 | |
| Celltrion USA INC. | $15.43 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $15.04 | 2023 | Suflave |
| Ferring Pharmaceuticals INC. | $14.70 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Piper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.